Drug Profile
Pentosan polysulfate - Paradigm Biopharma
Alternative Names: Pentosan polysulfate sodium - Paradigm Biopharma; PPS - Paradigm Biopharma; Rhinosul; ZILOSUL; ZilosulLatest Information Update: 29 Dec 2023
Price :
$50
*
At a glance
- Originator Glycan Biosciences; Griffith University
- Developer Griffith University; Paradigm Biopharma
- Class Analgesics; Anti-inflammatories; Antiallergics; Anticoagulants; Antihyperlipidaemics; Antiretrovirals; Antithrombotics; Antivirals; Glycosaminoglycans; Polymers; Polysaccharides; Small molecules; Sulfuric acids
- Mechanism of Action Cell membrane permeability inhibitors; Enzyme inhibitors; Non-nucleoside reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase III Pain
- Phase II Mucopolysaccharidosis VI; Ross River virus infections; Seasonal allergic rhinitis
- Phase I/II Mucopolysaccharidosis I; Oedema
- Preclinical Osteoarthritis
- No development reported Allergic asthma; Allergic rhinitis; Chikungunya virus infections; Chronic obstructive pulmonary disease
Most Recent Events
- 10 Nov 2023 Preclinical trials in Osteoarthritis in Australia (SC) prior to November 2023
- 10 Nov 2023 Pharmacodynamics and adverse events data from preclinical studies in Osteoarthritis presented at the ACR Convergence 2023 (ACR-ARP-2023) )
- 12 Aug 2022 Pentosan polysulfate - Paradigm Biopharma is available for licensing as of 12 Aug 2022. www.paradigmbiopharma.com 9365973